Is Glucosamine Worth Taking for Joint Pain? Why NDS Chooses Not to Use It
Share
Why NDS Does Not Use Glucosamine in Any of Its Joint Supplements
Glucosamine is one of the most widely sold joint supplements in the world. It is also one of the most inconsistent in its evidence, the most limited in its absorption, and now the subject of research linking it to accelerated cognitive decline in people with Alzheimer’s. Here is what you should know before taking it.
Walk into any health food retailer and glucosamine will occupy a prominent position on the joint health shelf. Taken by an estimated 40 million Americans alone, and by millions more across Europe and the UK, it has become the default response to joint pain in the supplement industry for decades.
But the science behind glucosamine is significantly more complicated than its market dominance suggests. The clinical evidence is inconsistent at best. Its bioavailability is poor. The largest independent trial ever conducted on it failed to show meaningful benefit over placebo. And new research published in June 2026 has raised a serious question about its safety in older adults.
At NDS, we have chosen not to include glucosamine in any of our joint supplements. This article explains why, using the evidence rather than marketing language.
The evidence problem: what the research actually shows
Glucosamine is derived from shellfish shells and functions as a natural component of cartilage matrix. The theoretical basis for supplementation is sound: it provides a substrate for cartilage repair and may help maintain joint structural integrity. The problem is that the clinical trials have never reliably confirmed this in practice.
The Glucosamine/Chondroitin Arthritis Intervention Trial, funded by the US National Institutes of Health, was the largest and most rigorous independent study ever conducted on glucosamine. It enrolled over 1,500 patients with knee osteoarthritis over six months.
The finding: glucosamine hydrochloride at 1,500mg daily was no more effective than placebo for knee osteoarthritis pain in the overall study population. Only a subgroup with moderate to severe pain showed any statistically significant benefit.
Cochrane Reviews examining the broader glucosamine literature have consistently found mixed results with significant heterogeneity across studies, meaning the research does not tell a consistent story, which is itself informative.
There is a meaningful distinction in the research between glucosamine hydrochloride (HCl) and glucosamine sulfate. The positive long-term trials, Reginster (2001) and Pavelka (2002), used pharmaceutical-grade crystalline glucosamine sulfate at a specific dose. Most over-the-counter supplements use glucosamine HCl, and the bioavailability of this form is substantially lower, which may explain why results from commercial supplements consistently underperform the pharmaceutical-grade studies.
This is not a minor technical point. It means that most people buying glucosamine from a health food shop may be buying a form with demonstrably inferior absorption to the version used in the positive trials.
The absorption problem: very little reaches the joint
Even in its most studied form, glucosamine has a documented bioavailability of approximately 25% from animal data. In practice, the compound is absorbed in the small intestine, undergoes significant first-pass metabolism in the liver, and only a fraction of what is consumed ultimately reaches articular cartilage tissue.
Pharmacokinetic data from the GAIT trial found that plasma glucosamine concentrations following glucosamine HCl supplementation were substantially lower than those achieved with pharmaceutical-grade glucosamine sulfate, even at equivalent stated doses. This disparity between label claim and actual tissue-level delivery is a fundamental limitation of glucosamine as a supplement ingredient.
Approximately 25% bioavailability from animal data. Significant first-pass liver metabolism reduces how much reaches target tissue.
The HCl form, the most common in supplements, achieves substantially lower plasma concentrations than the sulfate form used in positive trials.
Glucosamine provides substrate only. It does not signal chondroblasts to increase collagen synthesis, the mechanism that distinguishes bioactive peptides.
Results across studies are highly heterogeneous. Cochrane Reviews find no clear, consistent clinical benefit. The largest NIH-funded trial showed no benefit over placebo overall.
The new safety concern: glucosamine and Alzheimer’s progression
A study published in June 2026 in Nature Metabolism has raised a significant new concern about glucosamine use in older adults, the very population most likely to be taking it for joint pain.
Researchers found that people with Alzheimer’s disease who took glucosamine supplements were 25% more likely to die within five years than those with Alzheimer’s who did not take the supplement.
The study also found that those with mild cognitive impairment, the early stages of dementia, were more likely to progress to full Alzheimer’s when taking glucosamine.
In mice with Alzheimer’s-like symptoms given glucosamine, memory outcomes were worse. Conversely, blocking the enzyme that produces sugars like glucosamine actually improved dementia symptoms.
The proposed mechanism involves hyperglycosylation, the buildup of excess sugar coating on brain cells that is a feature of Alzheimer’s progression. Glucosamine, as a sugar-based molecule, may accelerate this process in people with existing cognitive impairment.
It is important to be precise about what this research does and does not show. The study was based on patient records and establishes an association rather than direct causation. One doctor commenting on the findings noted that patients with severe arthritis also commonly exhibit cognitive decline, meaning chronic pain itself may be a confounding variable.
What the research does establish, however, is that there is a meaningful question about glucosamine safety in older adults with cognitive vulnerability that did not previously exist in the evidence base. For a supplement whose efficacy evidence is already inconsistent, this additional safety signal matters.
Why tissue-specific collagen peptides take a fundamentally different approach
The reason NDS does not use glucosamine is not simply that we consider the evidence weak. It is that the underlying mechanism is limited in a way that tissue-specific collagen peptides are not.
Glucosamine provides raw substrate material. It does not communicate with the cells responsible for cartilage repair. It does not signal chondroblasts to increase collagen synthesis. It delivers building material without activating the builder.
NDS collagen peptides work on two fronts simultaneously. Approximately 10% of the peptide passes intact from the intestine directly to cartilage tissue, where it binds to receptors in chondroblasts and emits a biological signal that initiates the repair and reconstruction process. The remaining 90% is enzymatically broken down into dipeptides, tripeptides, and individual amino acids, primarily proline (25%) and glycine (20%), which are immediately incorporated as building material into the specific tissue that has been stimulated by the intact 10%.
This is the distinction that matters clinically. The 10% tells the tissue to rebuild. The 90% supplies everything needed to do it. One without the other is incomplete. Glucosamine only ever offers the second half of that equation, at poor bioavailability, with no signalling mechanism and inconsistent evidence of delivery.
- Provides raw material for cartilage
- Does not signal chondroblasts
- ~25% bioavailability at best
- Inconsistent clinical evidence
- Largest NIH trial: no overall benefit vs placebo
- New safety question in Alzheimer’s populations
- 10% absorbed intact, binds receptors in chondroblasts
- Signals genetic communication to rebuild cartilage
- 98.4% digestibility
- Incorporated into tissue twice as effectively as amino acids
- Tissue-specific: formulated specifically for cartilage
- Documented in human cell culture studies
The NDS position on joint supplementation: we formulate for biological specificity rather than market convention. CPF 218, the cartilage-specific peptide in NDS Collagen Ezy Move and Multi Collagen Total, targets chondroblasts directly. This is the standard we hold our formulations to. Glucosamine does not meet it.
- 10% of the peptide is absorbed intact and binds to receptors in chondroblasts, sending a direct biological signal to begin cartilage repair
- 90% is broken down into proline, glycine, and hydroxyproline, the exact amino acids that form the cartilage matrix, supplied directly to the tissue that has just been signalled to rebuild
- 98.4% digestibility, the highest documented in clinical research
- Incorporated into target tissue twice as effectively as individual amino acid supplements, documented in human cell culture studies
"The question we ask of every ingredient is not whether it is popular, but whether it does what we need it to do at a cellular level and whether the evidence holds up under scrutiny. Glucosamine fails on both counts compared with tissue-specific collagen peptides."
NDS Clinical Advisory, Nutritional Therapy
What this means practically
If you are currently taking a glucosamine supplement and have any degree of cognitive impairment, mild memory concerns, or a family history of Alzheimer’s disease, the June 2026 Nature Metabolism findings are worth discussing with your GP or a nutritional therapist before continuing.
If you are taking glucosamine specifically for joint health and have not seen meaningful results, the clinical literature suggests this is a common experience rather than an individual failure. The inconsistency in outcomes is well-documented and well-established in independent research.
The alternative approach of targeting the connective tissue directly with tissue-specific collagen peptides that both signal repair and supply building material is supported by a different and more mechanistically coherent body of evidence.
Frequently asked questions
Should I stop taking glucosamine immediately based on this research?
The Nature Metabolism study establishes an association, not proven causation. If you are otherwise healthy with no cognitive concerns, the findings are worth being aware of rather than immediately acting on. If you have mild cognitive impairment, early signs of dementia, or a family history of Alzheimer’s, discussing this research with your GP before continuing is a reasonable step.
Is there any population for whom glucosamine might still be appropriate?
Earlier research found that regular glucosamine use was associated with lower dementia risk in adults with healthy cognitive function, the opposite of the June 2026 findings in those with Alzheimer’s. The safety picture appears to differ significantly based on existing cognitive status. This is precisely why individual clinical assessment matters rather than generalised supplementation.
Why do so many joint supplements still contain glucosamine?
Market inertia. Glucosamine became a dominant joint supplement ingredient in the 1990s and 2000s based on early promising trials, and the industry largely continues to use it because consumers recognise the name. The more recent and more rigorous independent evidence, including the GAIT trial and the 2026 Alzheimer’s study, has not yet filtered into mainstream consumer awareness in the way the original positive studies did.
What does NDS use instead for joint support?
CPF 218, a bioactive collagen peptide with a documented molecular weight of 3 kDa, formulated to target chondroblasts in cartilage tissue. Human cell culture studies show it stimulates the genetic communication for cartilage rebuilding twice as effectively as products with similar labelling but no clinical documentation. It is the active peptide in NDS Collagen Ezy Move and one of the three tissue-specific fractions in NDS Multi Collagen Total.
Sources: Nature Metabolism, June 2026 (via NY Post / AOL News, June 23 2026); GAIT Trial, NIH-sponsored, New England Journal of Medicine (2006); Reginster et al. (2001); Cochrane Reviews on glucosamine and chondroitin; PMC pharmacokinetic review of glucosamine bioavailability; National Center for Health Research glucosamine evidence summary (2025); BodySpec evidence-based joint supplement guide (2025).